Novartis | NOVN - Cost Of Sales

Stock Price
130.50
Daily Change
2.40 1.87%
Monthly
14.27%
Yearly
33.63%
Q1 Forecast
123.39

Novartis reported $3.54B in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Alcon AG USD 1.16B 52M Sep/2025
Almirall EUR 191.5M 2.29M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Autolus Therapeutics Ltd USD 24.91M 6.96M Jun/2025
Bayer EUR 4.31B 57M Sep/2025
Biogen USD 810.1M 205.1M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Fresenius EUR 4.45B 262M Dec/2025
Fresenius Medical Care EUR 3.68B 38.37M Dec/2025
Galapagos EUR 84.73M 80.02M Sep/2025
Genmab DKK 57M 15M Jun/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
GRIFOLS EUR 1.13B 15.63M Sep/2025
Hikma Pharmaceutical USD 466.5M 428.5M Jun/2025
J&J USD 7.97B 689M Dec/2025
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.1B 123M Sep/2025
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 217M Sep/2025
Novartis USD 3.54B 216M Sep/2025
Novo Nordisk DKK 15.15B 2.3B Dec/2025
Orion EUR 186.6M 17.6M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Philips EUR 2.81B 417M Dec/2025
Recordati EUR 199.91M 20.12M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
UCB EUR 901M 50M Dec/2024